Algorithms used in telemonitoring programmes for patients with chronic heart failure: A systematic review

Maaike Brons¹, Stefan Koudstaal¹,² and Folkert W Asselbergs¹–⁴

Abstract

Introduction: Non-invasive telemonitoring programmes detecting deterioration of heart failure are increasingly used in heart failure care.

Aim: The aim of this study was to compare different monitoring algorithms used in non-invasive telemonitoring programmes for patients with chronic heart failure.

Methods: We performed a systematic literature review in MEDLINE (PubMed) and Embase to identify published reports on non-invasive telemonitoring programmes in patients with heart failure aged over 18 years.

Results: Out of 99 studies included in the study, 20 (20%) studies described the algorithm used for monitoring worsening heart failure or algorithms used for titration of heart failure medication. Most frequently used biometric measurements were bodyweight (96%), blood pressure (85%) and heart rate (61%). Algorithms to detect worsening heart failure were based on daily changes in bodyweight in 20 (100%) studies and/or blood pressure in 12 (60%) studies. In 12 (60%) studies patients were contacted by telephone in the case of measurements outside thresholds.

Conclusion: Only one in five studies on telemonitoring in chronic heart failure reported the algorithm that was used to detect worsening heart failure. Standardised description of the telemonitoring algorithm can expedite the identification of key components in telemonitoring algorithms that allow accurate prediction of worsening heart failure.

Keywords
Heart failure, telemonitoring programmes, monitoring algorithms

Date received: 21 December 2017; revised: 13 June 2018; accepted: 13 June 2018

Introduction

Chronic heart failure is a progressive clinical syndrome characterised by recurrent episodes of worsening heart failure. Patients with chronic heart failure benefit from regular follow-up and monitoring of biometric measurements and heart failure symptoms to detect deterioration of heart failure and to ensure the safety and optimal dosing of heart failure medication.¹ However, deterioration of heart failure is unpredictable and often not fully captured in the fixed visits the patient has with his or her healthcare professional.

Telemonitoring is a promising technique that can detect early deteriorations in heart failure in order to avoid hospital admissions. However, clinical trials regarding the effectiveness of telemonitoring in managing heart failure care have produced mixed results, in part because of differences in the telemedicine approaches used.²⁻⁴

In the last decades, non-invasive telemonitoring in heart failure has moved from structured telephone calls to remote management systems. In the case of remote management...

¹Department of Cardiology, University Medical Center Utrecht, The Netherlands
²Farr Institute of Health Informatics Research, University College London, UK
³Durrer Center for Cardiovascular Research, Netherlands Heart Institute, The Netherlands
⁴Institute of Cardiovascular Science, University College London, UK

Corresponding author:
Maaike Brons, Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Email: m.brons@umcutrecht.nl
systems, data from telemonitoring devices is linked into a
telemedical platform and sent to the telemedical centre,
hospitals or primary care provider.5

One of the key components in non-invasive telemo-
ntoring are biometric values (e.g. bodyweight, blood pres-
sure and heart rate), measured on a regularly basis by
patients at home.6 The use of biometric measurements in
non-invasive telemonitoring are based on the clinical pres-
entation of patients with deterioration of heart failure, such
as fluid overload (increased bodyweight), hypo- or hyper-
tension, or brady- or tachyarrhythmias.

Besides biometric measurements, heart failure status
questions are used for detection of deterioration and early
intervention to prevent (re)hospitalization. The topics are
mostly based on the clinical presentation of symptoms of
deterioration of heart failure (e.g. dyspnoea, oedema).

To monitor the values in non-invasive telemonitoring
programmes, there are several methods. The most com-
monly used method is based on manually reviewing biom-
etric measurements by a healthcare provider, who is often
helped by a protocol including thresholds and treatment
plans. Another method is automated algorithms integrated
in telemonitoring programmes.

At present, there is little evidence what combination of
biometric measurements and questionnaires of self-
reported symptoms is most effective in predicting deterio-
rating of heart failure. Besides the combination, thresholds
for these measurements are also less well studied. It stands
to reason that when set too wide, then there is a high risk
that the patient is decompensated before an alert trigger is
generated whereas thresholds which are set too tightly
could lead to many ‘false’ alert triggers.6

The aim of this systematic review was, first, to assess
how algorithms in non-invasive telemonitoring pro-
grammes were reported and, secondly, which subsequent
thresholds for biometric parameters (bodyweight, blood
pressure, heart rate) and symptom questions were used to
monitor symptoms of heart failure and/or guide titration of
heart failure medication.

Methods

We undertook this systematic review according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines. See the PRISMA
checklist in Supplementary Material Appendix 1.

Search strategy for identification of relevant
studies

A comprehensive search was conducted through the
MEDLINE (PubMed) and Embase (www.embase.com)
databases published until September 2017. Searched terms
expressing heart failure were used in combination with
terms identifying telemedicine. The full search strategy
can be found in Supplementary Material Appendix 2.

References of included studies were checked for additional
relevant articles.

Review methods and selection criteria

Two reviewers (MB and SK) independently screened all
titles and abstracts and made decisions regarding potential
eligibility after full-text review. Discrepancies in judgment
were resolved by a third reviewer (FA). We searched for
articles written in English containing published reports of
non-invasive telemedicine programmes (including tele-
phone support) using biometric data performed in patients
with heart failure aged over 18 years. We excluded publi-
cations: (a) addressing tele-rehabilitation only; (b) address-
ing tele-education only; (c) addressing telemonitoring
programmes continuously collecting biometric data; (d)
not monitoring patients at home; (e) not addressing an
intervention.

Data extraction

For each included study, the following information was
extracted: data source/study period, study location, number
of hospitals, number of patients, study outcome, interven-
tion, internal and external validity as reported by the authors.

Risk of bias in individual studies

We performed risk of bias assessments using the ‘Risk of
bias’ tool described in Chapter 8 of the Cochrane Handbook
for Systematic Reviews of Interventions (available from
http://handbook.cochrane.org).7 We assessed each study
according to the following quality domains: random
sequence generation, allocation concealment, participants
and personnel were aware/unaware of the treatment
assignments, blinding of outcome assessment, incomplete
outcome data, selective reporting and other biases
(Supplementary Material Appendix 3).

Summary measures and synthesis of results

The process of data synthesis was performed through a
descriptive analysis of the selected studies.

Results

Article selection and risks of bias assessment

The literature search (performed on 1 September 2017) iden-
tified 1457 publications in MEDLINE (n=1308) and Embase
(n=149). Out of 99 studies that met the inclusion and exclu-
sion criteria, 20 (20%) studies reported information on the
algorithm used (Figure 1). The detailed characteristics of the
20 studies that reported on the telemonitoring algorithm are
presented in Supplementary Material Appendix 4. In 16 stud-
ies, data were automatically transferred to a telemonitoring
service centre or trial site, and in four studies a mobile phone-based monitoring system was used.

No study was judged to be at low risk of bias (Supplementary Material Appendix 3).

**Biometric measurements and heart failure status questions in non-invasive telemonitoring programmes**

The most frequently used biometric parameters in telemonitoring in heart failure were bodyweight (96%), blood pressure (85%), heart rate (61%), oxygen saturation (23%), and heart rhythm (17%) (Figure 2). An electrocardiogram (ECG) (15%), holter (1%) or 15-second heart rhythm strip (1%) were used to detect the patient’s heart rhythm. Less frequently used biometric parameters were heart and lungs auscultation (via electronic stethoscope) (7%), body temperature (6%), blood glucose (5%), respiration rate (2%), international normalized ratio (INR) (1%), measurement of ankle circumference with tape (1%), a six-minute walk test using a telemedical accelerometer (1%) and measuring steps a day with a pedometer (1%). In 42% of the articles,

![Flow of studies through the review process.](image_url)
heart failure status questions were used in the algorithms such as ‘Do you feel breathing is more difficult?’ and ‘Have you felt more short of breath in the last day?’ (Supplementary Material Appendix 5. Heart failure status questions in telemonitoring systems). In all heart failure status questionnaires at least one question concerning dyspnoea was included.8–15 A question concerning oedema was included in six questionnaires.8,9,11,13–15

Only Kurtz et al., in 2011, described the use of an algorithm based on a decision tree with numeric scores and a total score.12 The algorithm contained three heart failure questions concerning bodyweight change (answer possibilities: no change (zero points), change <2 kg (one point), change >2 kg (two points)), dyspnoea (answer possibilities: breath unchanged (zero points), more short of breath (one point)) and general health status (stable (zero points), deteriorated (one point)).12

The Chronic Heart Failure Assessment by Telephone (CHAT) study used an algorithm including bodyweight and questions with regard to heart failure clinical status, medical management of the patient’s condition and social questions relevant to the patient’s heart failure status.8 The algorithm contained the following modules: exercise, medicine adherence, dehydration, arrhythmia, appointment, excess body fluid.8

In the study of Black et al., published in 2014, the thresholds set for biometric measurements were combined with alerts in heart failure status questions.11 For example when a patient had a systolic blood pressure of <90 mm Hg or >160 mm Hg with symptoms, then an urgent alert was generated. Without symptoms, the systolic blood pressure threshold was <80 mm Hg or >170 mm Hg.11

Biometric measurements and alert triggers

The biometric measurements and the use of heart failure symptom questionnaires in the algorithm are shown in Table 1. In the CHAT trial, heart failure status questions were specified but not the alert variance triggers of bodyweight (the only biometric parameter used in the study).8 In 2007, in the study of Gambetta et al., alert triggers were set for absolute and relative changes in signs, reporting of symptoms, and noncompliance to medication.9

In four articles authors noted physicians could change the biometric parameters, depending on the patient’s status.10,11,16,17

In most studies participants were asked to measure the biometric parameters daily (Table 2). The biometric alert triggers used in the articles are listed in Table 2, the used heart failure status questions are in Supplementary Material Appendix 5.

Monitoring of data by healthcare professionals

In 11 studies, alert triggers were monitored by a nurse.8,9,11,14,16–22 In one study both the general practitioner and healthcare professionals at the heart failure clinic monitored the data.23 In five studies it was less specifically described who monitored the data, because of the use of the general terms ‘clinician’ and ‘physician’.10,13,15,24,25 In three studies the healthcare professional (e.g. physician, nurse) who monitored the biometric values remained unclear.12,26,27 The frequency of monitoring biometric measurements varied between daily and three times a week.

Actions of healthcare professionals on alert triggers

In 12 studies, patients were contacted by telephone in the case of measurements outside thresholds.8,9,11,13–19,23,24,26,27 In the CardioBBEAT trial, the study site called the patient if biometric measurements were outside of the established limits. In six studies, it remained unclear how health professionals contacted patients (visits, telephone calls).8–10,20,21,25 In the Telemonitoring in the Management of Heart Failure (TEMA-HF) study a general practitioner visited or contacted the patient if the general practitioner considered it necessary. The heart failure nurse called the patient 1–3 days after the alert.22 Kurtz et al., in 2011, used an automated self-monitoring system.12 When measurements were stable (zero points) the patients were asked to repeat the measurements after a week, in the case of minor worsening (one point) after three days, in the case of suspected deterioration of heart failure (two points) to proceed a medical visit or to increase the frequency of telephone contacts and inform the patient’s physician, in the case of high risk of hospitalization (three points) according to the algorithm the patient were directly connected to a heart failure clinic healthcare professional.12 The actions taken by healthcare professionals who contacted the patients after an alert trigger varied between changes in medication treatment (in consultation with a cardiologist or with a general practitioner), further investigations or a scheduled consult of a cardiologist, nurse or general practitioner (deterioration of heart failure). The telemedicine system was checked again on
schedule within 2–3 days. In five studies (25%) it remained unclear which actions were taken after contacting the patient in the case of stable or deterioration of heart failure.8–10,17,25

Medication protocols

Changes in heart failure medication in the case of alert triggers remained unclear in most of the studies. In the WISH trial patients were asked to take an additional dose of their diuretics in the case of deterioration of heart failure.18 The CHAT trial used a diuretic protocol, but did not further specify the protocol.8 In the Trans-European Network-Home-Care Management System (TEN-HMS) trial a heart rate of $\leq 65$ bpm during the titration phase was an indication to delay further increase in dose of beta-blocker.20 The study of Spaeder et al., in 2006, consisted of rapid titration of carvedilol using a telemedical system versus frequent outpatient heart failure clinic visits.21

Discussion

In the present study, we assessed thresholds of algorithms in non-invasive telemonitoring programmes for symptoms of heart failure. First and foremost, we found that only one in five telemonitoring studies specified the algorithm used to monitor heart failure symptoms. The thresholds used for alert triggers in bodyweight, blood pressure and heart rate varied. Furthermore, the level of precision in measurement of bodyweight, blood pressure and heart rate remained unclear. With regard to heart failure status questionnaires, there was a wide range of topics and number of questions asked. Lastly, in the included articles, there was considerable heterogeneity in describing telemonitoring programmes and protocols.

The most common biometric measurement in telemonitoring was bodyweight and was mostly combined with other biometric measurements such as blood pressure or with heart failure status questions. In most studies nurses interpreted the data.8,9,11,14–22 Some articles used general terms as ‘clinician’ or ‘physician’ to indicate the healthcare professional monitoring the data and in three studies it remained unclear who interpreted the data. In most cases little information was given about the educational background of the healthcare professional monitoring the data concerning heart failure and interpretation of telemonitoring values. Thereby the relationship between knowledge and experience at monitoring data and effectiveness of a telemonitoring programme remains unclear. It may be valuable to report in articles the profession of the healthcare professional and in the case of nurses if they were specialised in heart failure and if he/she was educated in monitoring biometric data. Even though there is a wide diversity in nursing education in heart failure and in organization of heart failure care, within and

| Author               | Study          | Weight | Blood pressure | Heart rate | Symptom questions | Medication adjustments and alert triggers bodyweight, blood pressure, heart rate |
|----------------------|----------------|--------|----------------|------------|-------------------|--------------------------------------------------------------------------------|
| Biddis et al., 200910| BEAT-HF        | Yes    | Yes            | Yes        | Yes               | –                                                                              |
| Black et al., 201411 | Tele-HF        | Yes    | –              | –          | –                 | –                                                                              |
| Chaudhry et al., 200713| TEN-HMS       | Yes    | Yes            | Yes        | –                 | –                                                                              |
| Cleland et al., 200520| TEMA-HF        | Yes    | Yes            | Yes        | Yes               | Yes, beta-blocker                                                              |
| Dendale et al., 201222| CHAT           | Not specified | –          | –          | Yes               | –                                                                              |
| Giordano et al., 200923| CardioBBAT   | Yes    | Yes            | Yes        | –                 | –                                                                              |
| Hofmann et al., 201527| CHAT          | Not specified | –          | –          | Yes               | –                                                                              |
| Kurtz et al., 201112 | WISH           | Yes    | –              | –          | –                 | –                                                                              |
| Lyngå et al., 201218 | TELBIL         | Yes    | Yes            | Yes        | –                 | –                                                                              |
| Maric et al., 201014 | MOBITEL        | Yes    | Yes            | Yes        | –                 | –                                                                              |
| Martín-Lesende et al., 201117| –          | Yes    | Yes            | Yes        | –                 | –                                                                              |
| Morguet et al., 200826| CHAT           | Yes    | Yes            | Yes        | –                 | –                                                                              |
| Piette et al., 201523| –             | Yes    | –              | –          | –                 | –                                                                              |
| Roth et al., 200419 | –              | Yes    | Yes            | Yes        | –                 | –                                                                              |
| Scherr et al., 200924| –              | Yes    | Yes            | Yes        | –                 | Yes, carvedilol                                                                |
| Spaeder et al 200641 | –              | Yes    | Yes            | Yes        | –                 | –                                                                              |
| Wagenaar et al., 201515| E-Vita HF trial | Yes    | Yes            | Yes        | –                 | –                                                                              |
| White-Williams et al., 201521| –          | Yes    | Yes            | Yes        | –                 | –                                                                              |

BEAT-HF: Better Effectiveness After Transition – Heart Failure; CHAT: Chronic Heart Failure Assessment by Telephone; MOBITEL: MOBile TELemonitoring in Heart Failure Patients; Tele-HF: Telemonitoring to Improve Heart Failure Outcomes; TEMA-HF: Telemonitoring in the Management of Heart Failure; TEN-HMS: Trans-European Network-Home-Care Management System; WISH: Weight monitoring in patients with severe heart failure.
| Author                  | Study          | Bodyweight variance alert triggers                                                                                                                                                                                                                                                                                                                                                                                                            | Blood pressure (mm Hg)                                                                                                                                                                                                                                                                                                                                 | Heart rate, beats/min                                                                 | Frequency |
|-------------------------|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| Biddis et al., 200910   |                | Increase 0.91 kg \(^{e}\) since previous day or if weight increases by 1.36 kg \(^{e}\) in a rolling 7 days \(^{3}\)                                                                                                                                                                                                                                                                                                                                 | Systolic: <100 or drops by 20 from previous reading                                                                                                                                                                                                                                                                                                                                 | Diastolic: -                                                                                                                                                                                                 | Daily      |
| Black et al., 201411    | BEAT-HF        | With symptoms\(^{3}\) Daily gain >1.36 kg \(^{e}\) or weekly gain >2.72 kg \(^{e}\)                                                                                                                                                                                                                                                                                                                                                                | With symptoms\(^{3}\) <90 or >160                                                                                                                                                                                                                                                                                                                                 | Diastolic: -                                                                                                                                                                                                 | Daily      |
| Chaudhry et al., 200713 | Tele-HF        | >1.36 kg \(^{e}\) above or below first bodyweight entered                                                                                                                                                                                                                                                                                                                                                                                   | Without symptoms <80 or >170                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                   | Daily      |
| Cleland et al., 200510  | TEN-HMS        | >2 kg weight gain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Systolic: <90 or >140                                                                                                                                                                                                                                                                                                                                                         | Diastolic: -                                                                                                                                                                                                 | Twice daily |
| Dendale et al., 201222  | TEMA-HF        | +2 kg from discharge bodyweight                                                                                                                                                                                                                                                                                                                                                                                                           | Systolic: <90 or >140                                                                                                                                                                                                                                                                                                                                                         | Diastolic: -                                                                                                                                                                                                 | Daily      |
| Gambetta et al., 2007\(^{5}\) |                | A weight change of 1.36 kg \(^{e}\) in 3 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | -                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                   | Daily      |
| Hofmann et al., 201527  | Cardio-BBEAT  | Increase >2 kg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Dizziness with <90                                                                                                                                                                                                                                                                                                                                                         | Diastolic: -                                                                                                                                                                                                 | Daily      |
| Krum et al., 2013\(^{3}\) | CHAT           | Weight change <2 kg or >2 kg                                                                                                                                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                   | Monthly    |
| Kurtz et al., 201112    |                | Weight change <2 kg or >2 kg                                                                                                                                                                                                                                                                                                                                                                                                             | -                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                   | Weekly     |
| Lyngå et al., 201218    | WISH           | >2 kg weight gain in 3 days                                                                                                                                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                   | Daily      |
| Martín-Lesende et al., 2011\(^{17}\) | TELBIL | >1 kg within 3 days                                                                                                                                                                                                                                                                                                                                                                                                                                | Systolic: <100 or >160 Diastolic: <60 or >90                                                                                                                                                                                                                                                                                                                                | Diastolic: <50 or >100                                                                                                               | Daily      |
| Morguet et al., 200826  |                | >1.5 kg                                                                                                                                                                                                                                                                                                                                                                                                                                           | Systolic: <90 or >180 Diastolic: >110                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                   | Daily      |
| Piette et al., 2015\(^{15}\) |                | Increase of 2.27 kg \(^{e}\) over 1 or 2 weeks, a 3.18 kg \(^{e}\) increase over 3 weeks, or an average gain of 0.91 kg \(^{e}\) per week since the last automated call if more than 3 weeks had elapsed                                                                                                                                                                                                            | -                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                   | Daily      |
| Roth et al., 2004\(^{19}\) |                | >1.5 kg compared to baseline                                                                                                                                                                                                                                                                                                                                                                                                                  | Systolic: <90 or >180 Diastolic: >110                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                   | Daily      |
| Scherr et al., 200924   | MOBITEL        | Increased or decreased more than 2 kg in 2 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | -                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                   | Daily      |
| Spaeder et al., 200621  |                | Carvedilol titration                                                                                                                                                                                                                                                                                                                                                                                                                             | Between 85–99                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                   | Daily      |
| Wagenaar et al., 201516 | E-Vita HF trial | +1 kg in 1 day, +2 kg in three consecutive days, -3 kg in 1 day and +2 kg or -2 kg from baseline bodyweight                                                                                                                                                                                                                                                                       | Average <90 or >140 for 3 consecutive days Average <50 or >100 for 3 consecutive days                                                                                                                                                                                                                                                                                      | Diastolic: Vary >10 mm Hg Vary >10 mm Hg                                                                                             | Daily      |
| White-Williams et al., 2015\(^{15}\) |                | >2.27 kg \(^{e}\) increase                                                                                                                                                                                                                                                                                                                                                                                                                      | Vary >10 mm Hg                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                   | Daily      |

\(^{e}\)Pounds to kilogram conversion (1 lb=0.45359237 kg).

BEAT-HF: Better Effectiveness After Transition – Heart Failure; CHAT: Chronic Heart Failure Assessment by Telephone; MOBITEL: MOBILE TELEmonitoring in Heart Failure Patients; Tele-HF: Telemonitoring to Improve Heart Failure Outcomes; TEMA-HF: Telemonitoring in the Management of Heart Failure; TEN-HMS: Trans-European Network-Home-Care Management System; WISH: Weight monitoring in patients with severe heart failure.
between countries, this could help to interpret the findings of scientific research.28,29

Furthermore, the description of the actions taken in the case of an alert trigger can be informative. In six studies it remained unclear how healthcare professionals contacted patients in the case of an alert trigger (visits, telephone calls, video consult), which subsequent actions were taken (fixing a new scheduled appointment (stable conditions) and if medication were changed (e.g. in consultation with cardiologist or with general practitioner)).8–10,20,21,25 In these studies it remained unclear how the actions taken on alert triggers affected the findings of the trial.

Underreported in articles were medication titration protocols used in telemonitoring programmes in heart failure. In one study, the TEN-HMS study, a threshold for heart rate was reported to delay further increase in dose of beta-blocker.20 Medication titration algorithms for angiotensin-converting-enzyme inhibitor (ACEi), angiotensin II inhibitor (ARB), beta-blockers, mineralocorticoid receptor antagonists (MRAs) were not identified. The WISH and CHAT studies reported loop diuretic adjustments, but did not specify them.8,18 As medication protocols remain underexposed in telemedicine articles, the effects of medication changes on the results of telemedicine studies remain to be elucidated.

In the field of telemonitoring of heart failure, the view is arising that it is of paramount importance to increase comparability between telemonitoring studies.2–4 Not only the description of both the intervention (e.g. telemedical system used, contacts with healthcare professionals) and usual care provide important information, but also algorithms, level of precision in measurement of biometric equipment, information about monitoring data and actions taken on values outside thresholds provide meaningful insights. The importance of specifying telemonitoring algorithms may be seen to be particularly helpful for the monitoring of bodyweight. Monitoring of daily bodyweight is recommended in chronic heart failure and there is substantial heterogeneity in published rule-of-thumb thresholds that define clinically important bodyweight gain that can indicate deterioration of heart failure.30 Several research groups reported that simple rules of sudden bodyweight change in patients with heart failure were demonstrated to generate many alerts with poor sensitivity.6,30–32

Different methods are being used to interpret values outside thresholds in telemonitoring chronic heart failure. Some telemonitoring programmes depend only on knowledge of the healthcare professional interpreting the data. Other telemonitoring programmes use automated algorithms to monitor data and issue an alarm in the case of values outside the established thresholds. The healthcare professional subsequently interprets the alarm and decides which actions to take (with or without use of a protocol).

Most of the automated algorithms used in monitoring early deterioration of heart failure are decision-tree and threshold-based. In the nearby future, more personalised self-learning automated algorithms (machine-learning methods) will likely be used in monitoring early deterioration of heart failure.

Study limitations

The systematic review was limited by the amount and nature of the data available. We limited the review to fully published studies.

Conclusions

Only one in five studies on non-invasive telemonitoring of chronic heart failure reported the algorithm that was used to detect worsening heart failure. The most commonly used biometric parameter in non-invasive telemonitoring in heart failure is bodyweight. Standardised description of the telemonitoring algorithm can expedite the identification of key components in telemonitoring algorithms that allow accurate prediction of worsening heart failure.

Implications for practice

- Little is known about algorithms used to detect deterioration of heart failure. Standardised reporting of algorithms used and the actions taken on alarms can help to compare telemonitoring programmes more effectively.
- It may be valuable to report in articles the profession of the healthcare professional and in the case of nurses whether they were specialised in heart failure and if educated in monitoring biometric data.
- As medication protocols remain underexposed in telemedicine articles, the effect of medication changes on the results of telemedicine studies remains to be elucidated.

Authors contribution

All authors wrote, reviewed and edited the manuscript before submission.

Declaration of conflicting interests

The authors declare that there is no conflict of interest.

Funding

Folkert W Asselbergs is supported by University College London (UCL) Hospitals National Institute for Health Research (NIHR) Biomedical Research Centre.

References

1. Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart
failure. 
The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Euro J Heart Fail* 2011; 13: 891–975.

2. Inglis SC, Clark RA, Dierckx R, et al. Structured telephone support or non-invasive telemonitoring for patients with heart failure. *Cochrane Database Syst Rev* 2015; 10: CD007228.

3. Koehler F, Winkler S, Schieber M, et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: The Telemedical Interventional Monitoring in Heart Failure study. *Circulation* 2011; 123: 1873–1880.

4. Chaudhry SI, Mattera JA, Curtis JP, et al. Telemonitoring in patients with heart failure. *N Engl J Med* 2010; 363: 2301–2309.

5. Anker SD, Koehler F and Abraham WT. Telemedicine and remote management of patients with heart failure. *Lancet* 2011; 378: 731–739.

6. Cuba Gyllensten I, Crundall-Goode A, Aarts RM, et al. Simulated case management of home telemonitoring to assess the impact of different alert algorithms on work-load and clinical decisions. *BMJ Med Inform Decis Mak* 2017; 17: 11.

7. Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org.

8. Krum H, Forbes A, Yallop J, et al. Telephone support to rural and remote patients with heart failure: The Chronic Heart Failure Assessment by Telephone (CHAT) study. *Cardiovasc Ther* 2013; 31: 230–237.

9. Gambetta M, Dunn P, Nelson D, et al. Impact of the implementation of telemangement on a disease management program in an elderly heart failure cohort. *Prog Cardiovasc Nurs* 2007; 22: 196–200.

10. Biddiss E, Brownell S and Hawley MS. Predicting need for intervention in individuals with congestive heart failure using a home-based telecare system. *J Telemed Telecare* 2009; 15: 226–231.

11. Black JT, Romano PS, Sadeghi B, et al. A remote monitoring and telephone nurse coaching intervention to reduce readmissions among patients with heart failure: Study protocol for the Better Effectiveness After Transition – Heart Failure (BEAT-HF) randomized controlled trial. *Trials* 2014; 15: 124–135.

12. Kurtz B, Lemercier M, Pouchin SC, et al. Automated home telephome self-monitoring reduces hospitalization in patients with advanced heart failure. *J Telemed Telecare* 2011; 17: 298–302.

13. Chaudhry SI, Barton B, Mattera J, et al. Randomized trial of telemonitoring to improve heart failure outcomes (tele-HF): Study design. *J Card Fail* 2007; 13: 709–714.

14. Marie B, Kaan A, Araki Y, et al. The use of the Internet to remotely monitor patients with heart failure. *Telemed J E Health* 2010; 16: 26–33.

15. White-Williams C, Unruh L and Ward K. Hospital utilization after a telemonitoring program: A pilot study. *Home Health Care Serv Q* 2015; 34: 1–13.

16. Wagenaar KP, Broekhuizen BD, Dickstein K, et al. Effectiveness of an interactive platform, and the ESC/HFA heartfailurematters.org website in patients with heart failure: Design of the multicentre randomized e-Vita heart failure trial. *Euro J Heart Fail* 2015; 17: 1310–1316.

17. Martin-Lesende I, Orruno E, Cairo C, et al. Assessment of a primary-care-based telemonitoring intervention for home care patients with heart failure and chronic lung disease. The TELBIL study. *BMC Health Serv Res* 2011; 11: 56–68.

18. Lyngá P, Persson H, Hagg-Martineall A, et al. Weight monitoring in patients with severe heart failure (WISH). A randomized controlled trial. *Euro J Heart Fail* 2012; 14: 438–444.

19. Roth A, Kajiloti I, Elkayam I, et al. Telecardiology for patients with chronic heart failure: The ‘SHL’ experience in Israel. *Int J Cardiol* 2004; 97: 49–55.

20. Cleland JG, Louis AA, Rigby AS, et al. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: The Trans-European Network-Home-Care Management System (TEN-HMS) study. *J Am Coll Cardiol* 2005; 45: 1654–1664.

21. Spaeder J, Najjar SS, Gerstenblith G, et al. Rapid titration of carvedilol in patients with congestive heart failure: A randomized trial of automated telemedicine versus frequent outpatient clinic visits. *Am Heart J* 2006; 151: 844–845.

22. Dendale P, De Keulaenra G, Troisfontaines P, et al. Effect of a telemonitoring-facilitated collaboration between general practitioner and heart failure clinic on mortality and rehospitalization rates in severe heart failure: The TEMA-HF 1 (TElemonitoring in the MAnagement of Heart Failure) study. *Euro J Heart Fail* 2012; 14: 333–340.

23. Giordano A, Scalvini S, Zanelli E, et al. Multicenter randomised trial on home-based telemangement to prevent hospital readmission of patients with chronic heart failure. *Int J Cardiol* 2009; 131: 192–199.

24. Scherr D, Kastner P, Kollmann A, et al. Effect of home-based telemmonitoring using mobile phone technology on the outcome of heart failure patients after an episode of acute decompensation: Randomized controlled trial. *J Med Internet Res* 2009; 11: e34.

25. Piete JD, Striplin D, Marinec N, et al. A mobile health intervention supporting heart failure patients and their informal caregivers: A randomized comparative effectiveness trial. *J Med Internet Res* 2015; 17: e142.

26. Morguet AJ, Kuhnelt P, Kallel A, et al. Impact of telemedical care and monitoring on morbidity in mild to moderate chronic heart failure. *Cardiology* 2008; 111: 134–139.

27. Hofmann R, Voller H, Nagels K, et al. First outline and baseline data of a randomized, controlled multicenter trial to evaluate the health economic impact of home telemonitoring in chronic heart failure – CardioBBEAT. *Trials* 2015; 16: 343–155.

28. Riley JP, Astin F, Crespo-Leiro MG, et al. Heart Failure Association of the European Society of Cardiology heart failure nurse curriculum. *Euro J Heart Fail*. 2016; 18: 736–743.

29. Working Group of the Education Committee of the ESC Council on Cardiovascular Nursing and Allied Professions;
Working Group of the Education Committee of the ESC Council on Cardiovascular Nursing and Allied Professions. Education for nurses working in cardiovascular care: A European survey. *Eur J Cardiovasc Nurs* 2014; 13: 532–540.

30. Zhang J, Goode KM, Cuddihy PE, et al. Predicting hospitalization due to worsening heart failure using daily weight measurement: Analysis of the Trans-European Network-Home-Care Management System (TEN-HMS) study. *Eur J Heart Fail* 2009; 11: 420–427.

31. Ledwidge MT, O’Hanlon R, Lalor L, et al. Can individualized weight monitoring using the HeartPhone algorithm improve sensitivity for clinical deterioration of heart failure? *Eur J Heart Fail* 2013; 15: 447–455.

32. Anand IS, Tang WHW, Greenberg BH, et al. Design and performance of a multisensor heart failure monitoring algorithm: Results from the Multisensor Monitoring in Congestive Heart Failure (MUSIC) study. *J Card Fail* 2012; 18: 289–295.